Vaxart's Oral Vaccine For Stomach Bug Shows Reduction In Infection Rate
Portfolio Pulse from Vandana Singh
Vaxart Inc has released topline data from the Phase 2 challenge study of its oral tablet monovalent norovirus vaccine candidate, showing a statistically significant 29% reduction in the rate of norovirus infection between the vaccinated and placebo arms. The study also showed an 85% decrease in viral shedding in the vaccine arm compared with placebo. Vaxart is currently conducting additional analyses of the data from this challenge study and its prior norovirus trials to define the timing of a larger Phase 2b study. VXRT shares are down 6.56% at $0.75 on the last check Thursday.
September 07, 2023 | 3:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vaxart's Phase 2 study results for its oral norovirus vaccine candidate show promising results, potentially leading to a larger Phase 2b study. However, the company's shares have fallen by 6.56%.
The positive results from Vaxart's Phase 2 study of its oral norovirus vaccine candidate could potentially lead to a larger Phase 2b study, indicating progress in the company's vaccine development. However, despite these promising results, the company's shares have fallen by 6.56%, indicating a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100